Kurse werden geladen...
Prognose
| Kaufen | 1 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
| Dividenden-Strategie | 0 / 15 |
| HGI-Strategie | 0 / 18 |
| Levermann-Strategie | -4 / 13 |
News
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of two key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612): Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven. Each has 15 satellite locations. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as H1-2026.» Mehr auf globenewswire.com
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to report that the independent Data Safety Monitoring Board (DSMB) has completed its third scheduled safety data review of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in metastatic breast cancer (NCT06072612).» Mehr auf globenewswire.com
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces today that the Company will be conducting two virtual investor presentations on Thursday, June 12, at 12:00 PM EDT and on Thursday, June 26, at 12:00 PM EDT, arranged by Renmark Financial Communications Inc. Briacell Therapeutics Corp. welcomes stakeholders, investors, and other individual followers to register and attend these live events.» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | Jan. 2025 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | 100,00% |
| Nettoeinkommen | −6,07 Mio | 41,93% |
| EBITDA | −6,89 Mio | 24,21% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 16,76 Mio€ |
Anzahl Aktien | 6,78 Mio |
52 Wochen-Hoch/Tief | 8,34€ - 0,30€ |
| Dividenden | Nein |
Beta | 1,7 |
KGV (PE Ratio) | −0,69 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 2,21 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
BriaCell Therapeutics Corp. ist ein immunonkologisches Biotechnologieunternehmen, das sich mit der Entwicklung von Immuntherapien für die Behandlung von Krebs befasst. Der führende Kandidat ist Bria-IMT, der sich in einer klinischen Studie der Phase I/IIa in Kombination mit Immun-Checkpoint-Inhibitoren zur Behandlung von Brustkrebs befindet. Das Unternehmen hat außerdem eine kooperative Forschungs- und Entwicklungsvereinbarung mit dem National Cancer Institute zur Entwicklung von Bria-OTS, einer personalisierten Immuntherapie für fortgeschrittenen Brustkrebs, und BriaDx, einem diagnostischen Test. Der Hauptsitz von BriaCell Therapeutics Corp. befindet sich in West Vancouver, Kanada.
| Name | Briacell Therapeutics Corp. Registered Shares o.N. |
| CEO | William V. Williams FCPA, |
| Sitz | West Vancouver, bc Kanada |
| Website | |
| Industrie | Chemikalien |
| Börsengang | |
| Mitarbeiter | 16 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | BCTX |
Frankfurt | 8BTA.F |
München | 8BTA.MU |
Assets entdecken
Shareholder von Briacell Therapeutics Corp. Registered Shares o.N. investieren auch in folgende Assets
